Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month. Going off of that, we're profiling XBI's three biggest holdings, Novavax Inc (NASDAQ:NVAX), Insmed Inc. (NASDAQ:INSM), and Moderna Inc (NASDAQ:MRNA).
NVAX is down 12.4% to trade at $15.91 today, with no specific catalyst to explain the gap lower, and on track for its worst single-session loss since Feb. 28. Thanks to the Sanofi (SNY) deal earlier in May, NVAX is up 226% in 2024. The security fresh off a June 6, 52-week high of $23.85 as well.
INSM is up 6.7% to trade at $60.64, and earlier hit a record high of $60.47, thanks to a price-target hike to $85 from $75 at Leerink. The shares are up 93% so far in 2024, and have come a long way since this year's May 24 low of $21.92.
Moderna stock is 1.7% lower to trade at $147.77 at last check, despite phase three trial data that indicated its combined Covid-19 and flu shot provided better protection than its standalone shots. MRNA is up 49.2% in 2024, forming a bull flag pattern on the charts.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
